1. ScholarBank@NUS
  2. 1. Staff
  3. Staff Publications
Please use this identifier to cite or link to this item: https://doi.org/10.1186/s12957-015-0657-8
DC FieldValue
dc.titleClinicopathological significance of KAI1 expression and epithelial-mesenchymal transition in non-small cell lung cancer
dc.contributor.authorZhou, L
dc.contributor.authorYu, L
dc.contributor.authorWu, S
dc.contributor.authorFeng, Z
dc.contributor.authorSong, W
dc.contributor.authorGong, X
dc.date.accessioned2020-10-27T10:56:12Z
dc.date.available2020-10-27T10:56:12Z
dc.date.issued2015
dc.identifier.citationZhou, L, Yu, L, Wu, S, Feng, Z, Song, W, Gong, X (2015). Clinicopathological significance of KAI1 expression and epithelial-mesenchymal transition in non-small cell lung cancer. World Journal of Surgical Oncology 13 (1) : 234. ScholarBank@NUS Repository. https://doi.org/10.1186/s12957-015-0657-8
dc.identifier.issn14777819
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/181441
dc.description.abstractBackground: KAI1 and epithelial-mesenchymal transition (EMT) is related to both angiogenesis and lymphangiogenesis and is an important target in new cancer treatment strategies. We aimed to investigate the KAI1 and marker of EMT expression and correlation with lymph node metastasis (LNM) and explore their prognostic impact in non-small cell lung cancer (NSCLC). Methods: Tumor tissue specimens from 312 resected patients with stage I-IIIA NSCLC were obtained. Immunohistochemistry was used to assess the expression of the molecular markers KAI1, E-cadherin (E-cad), vimentin, CD34, and D2-40. Results: There were 153N0 and 159N+ patients. Tumor cell expression of KAI1and the marker of EMT, lymphatic vessel density (LVD), and microvessel density (MVD) were related to LNM. In multivariate analyses, the ages of patients, high tumor cell KAI1 expression, EMT, and the scores of MVD were independent factor of prognosis. Conclusions: Tumor cell KAI1 expression, EMT, LVD, and MVD correlate with LNM. Thus, the detection of KAI1, expression of markers of EMT, and the scores of MVD may be used as a potential indicator of NSCLC prognosis. © 2015 Zhou et al.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20201031
dc.subjectbiological marker
dc.subjectCD34 antigen
dc.subjectCD82 antigen
dc.subjectmonoclonal antibody D2-40
dc.subjectuvomorulin
dc.subjectvimentin
dc.subjectcadherin
dc.subjectCD82 antigen
dc.subjectCD82 protein, human
dc.subjecttumor marker
dc.subjectvimentin
dc.subjectadult
dc.subjectage distribution
dc.subjectArticle
dc.subjectcancer grading
dc.subjectcancer prognosis
dc.subjectcancer staging
dc.subjectcapillary density
dc.subjectcontrolled study
dc.subjectdisease marker
dc.subjectepithelial mesenchymal transition
dc.subjectfemale
dc.subjectfollow up
dc.subjecthuman
dc.subjecthuman tissue
dc.subjectimmunohistochemistry
dc.subjectlymph node metastasis
dc.subjectlymphatic parameters
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectnon small cell lung cancer
dc.subjectprotein analysis
dc.subjectprotein expression
dc.subjectprotein function
dc.subjectretrospective study
dc.subjectadenocarcinoma
dc.subjectenzyme immunoassay
dc.subjectlarge cell carcinoma
dc.subjectlung tumor
dc.subjectlymphangiogenesis
dc.subjectmetabolism
dc.subjectmiddle aged
dc.subjectmortality
dc.subjectnon small cell lung cancer
dc.subjectpathology
dc.subjectprognosis
dc.subjectsquamous cell carcinoma
dc.subjectsurvival rate
dc.subjecttumor invasion
dc.subjectAdenocarcinoma
dc.subjectAntigens, CD82
dc.subjectBiomarkers, Tumor
dc.subjectCadherins
dc.subjectCarcinoma, Large Cell
dc.subjectCarcinoma, Non-Small-Cell Lung
dc.subjectCarcinoma, Squamous Cell
dc.subjectEpithelial-Mesenchymal Transition
dc.subjectFemale
dc.subjectFollow-Up Studies
dc.subjectHumans
dc.subjectImmunoenzyme Techniques
dc.subjectLung Neoplasms
dc.subjectLymphangiogenesis
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectNeoplasm Grading
dc.subjectNeoplasm Invasiveness
dc.subjectNeoplasm Staging
dc.subjectPrognosis
dc.subjectRetrospective Studies
dc.subjectSurvival Rate
dc.subjectVimentin
dc.typeArticle
dc.contributor.departmentMEDICINE
dc.description.doi10.1186/s12957-015-0657-8
dc.description.sourcetitleWorld Journal of Surgical Oncology
dc.description.volume13
dc.description.issue1
dc.description.page234
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1186_s12957-015-0657-8.pdf1.55 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons